TacrolimusImmunosuppressive AgentsKidney TransplantationGraft RejectionCyclosporineGraft SurvivalMycophenolic AcidTransplantsTransplantation, HomologousOintmentsHeart TransplantationTissue DonorsTransplantationLiver TransplantationLung TransplantationTreatment OutcomeCalcineurinImmunosuppressionLiving DonorsSirolimusTime FactorsBone Marrow TransplantationRetrospective StudiesDrug Therapy, CombinationPostoperative ComplicationsDrug MonitoringTissue and Organ ProcurementGraft vs Host DiseaseHematopoietic Stem Cell TransplantationCytochrome P-450 CYP3ATransplantation ImmunologyFollow-Up StudiesAntilymphocyte SerumLiver FailureAdrenal Cortex HormonesHistocompatibility TestingWaiting ListsKidneyAdministration, TopicalCytomegalovirus InfectionsKidney Failure, ChronicCadaverBiopsyDermatologic AgentsTransplantation ConditioningProspective StudiesFetal Tissue TransplantationCreatininePancreas TransplantationImmunocompromised HostDrug InteractionsRecurrenceEmollientsRisk FactorsDose-Response Relationship, DrugKidney DiseasesDermatitis, AtopicSurvival RateSteroidsTacrolimus Binding Protein 1AIslets of Langerhans TransplantationKidney Function TestsHematologic NeoplasmsHistocompatibilityLiver DiseasesAcute DiseaseAdministration, OralSurvival AnalysisBK VirusHeart-Lung TransplantationDrug Administration SchedulePolyomavirus InfectionsArea Under CurveIncidenceBrain Tissue TransplantationGlomerular Filtration RateTransplantation, AutologousPostoperative PeriodHLA AntigensPrednisolonePrednisoneBronchiolitis ObliteransTransplantation, HeterotopicInfectionDelayed-Action PreparationsMonitoring, Immunologic